Q4 25 EPS
$2.33
BEAT +308.97%
Est. $-1.12
Q4 25 Revenue
$114.1M
BEAT +781.34%
Est. $12.9M
vs S&P Since Q4 25
+4.1%
BEATING MARKET
BEAM +11.5% vs S&P +7.4%
Full Year 2025 Results
FY 25 EPS
$-0.81
BEAT +81.08%
Est. $-4.28
FY 25 Revenue
$139.7M
BEAT +262.99%
Est. $38.5M
Market Reaction
Did BEAM Beat Earnings? Q4 2025 Results
Beam Therapeutics delivered a striking earnings beat in Q4 2025, posting adjusted EPS of $2.33 against a consensus estimate of negative $1.01, a positive surprise of 330.69%, while revenue of $114.11 million cleared the $12.86 million consensus by 78… Read more Beam Therapeutics delivered a striking earnings beat in Q4 2025, posting adjusted EPS of $2.33 against a consensus estimate of negative $1.01, a positive surprise of 330.69%, while revenue of $114.11 million cleared the $12.86 million consensus by 787.07% and rose 279.5% from the year-ago quarter. The headline driver was a $255.15 million gain on the sale of an equity method investment, which pushed the company to GAAP net income of $244.30 million compared to a net loss of $90.35 million a year earlier; absent that one-time item, Beam would have remained in the red. Revenue itself was propelled by Pfizer's opt-in to an exclusive worldwide license for a liver-targeted development candidate, concluding a four-year research collaboration. Looking ahead, Beam extended its cash runway into mid-2029, supported by a $1.25 billion year-end cash position and a new $500.00 million credit facility with Sixth Street, with key catalysts including a potential BLA submission for risto-cel in sickle cell disease as early as year-end 2026 and updated BEAM-302 data expected by the close of Q1 2026.
Key Takeaways
- • Gain on sale of equity method investment of $255.1 million drove Q4 net income
- • License and collaboration revenue of $114.1 million in Q4 2025 versus $30.1 million in Q4 2024, reflecting Pfizer collaboration activities
- • Strong cash position of $1.25 billion at year-end bolstered by collaboration payments and financing
BEAM YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development paths to approval across multiple high-value programs.”
— John Evans, Q4 2025 Earnings Press Release
BEAM Earnings Trends
BEAM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BEAM EPS Trend
Earnings per share: estimate vs actual
BEAM Revenue Trend
Quarterly revenue: estimate vs actual
BEAM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-1.01 | $-0.91 | +10.06% | $31.7M | +159.70% |
| Q4 25 BEAT FY | $-1.12 | $2.33 | +308.97% | $114.1M | +781.34% |
| FY Full Year | $-4.28 | $-0.81 | +81.08% | $139.7M | +262.99% |
| Q3 25 MISS | $-1.03 | $-1.10 | -7.10% | $9.7M | -23.79% |
| Q2 25 BEAT | $-1.09 | $-1.00 | +8.37% | $8.5M | -36.31% |
| Q1 25 MISS | $-1.17 | $-1.24 | -5.86% | $7.5M | -49.13% |